Goldman Sachs raised the firm's price target on Protagonist Therapeutics to $110 from $97 and keeps a Neutral rating on the shares. The price target increase is driven mainly by the inclusion of icotrokinra in psoriatic arthritis at an 80% probability of success given upcoming Phase 3 readouts, with assumed U.S. and EU launches in 2028, the analyst tells investors in a research note.
